Stem-cell firm ReNeuron Group Plc (RENE.L: Quote, Profile, Research) said on Friday that initial tests on its stroke treatment ReNOO1 found it did not form tumours, a factor it says is key for approval to carry out human trials.
Stem-cell firm ReNeuron Group Plc (RENE.L: Quote, Profile, Research) said on Friday that initial tests on its stroke treatment ReNOO1 found it did not form tumours, a factor it says is key for approval to carry out human trials.
